PROTEOMICS SHARED RESOURCE The Proteomics SR (PROT) is a state-of-the-art facility that brings cutting edge proteomics research to LCCC faculty. It is a well-established shared resource (SR) that provides consultation for the design of experiments, sample preparation, mass spectrometry (MS) and extensive data analysis for LCCC members. Directed by an expert staff, the SR is full service allowing users with projects but little experience to understand the range of data acquisition opportunities. The SR also has the instrumentation that allows more experienced users access to expensive, well maintained mass spectrometers. Core staff and expert users have extended the capabilities with innovative techniques such as the MIB/MS analysis of cell wide kinase activity. Contributions include validating and characterizing cancer-relevant drug targets, quantifying proteome and signaling network changes in response to emerging therapeutics, studying the dynamic regulation of the kinome, describing how specific pathways globally remodel cancer proteomes independent of changes in gene expression, and determining how protein interaction networks are dysregulated in cancer. Instrumentation includes; state-of-the-art mass spectrometers include: Thermo Lumos, Thermo QExactive HF- X, Thermo QExactive Biopharma, Thermo QExactive HF, Thermo Orbitrap Velos and Sciex 5800 MALDI/TOF/TOF. All were partially purchased or leased by LCCC including four within the last four years. The purchase and maintenance of the current PROT SR instruments are beyond the means of any individual lab. LCCC investments have made it possible for multiple labs to access high end technology. The cost of PROT SR services are generally lower by 25% than comparable private company or other academic institutions and LCCC members receive an additional discount making the facility quite cost effective. The LCCC is requesting $135,301 from the CCSG, which represents 21% of the total operating budget; 48% of the SR usage is by LCCC faculty.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Anderson, Chelsea; Engel, Stephanie M; Anders, Carey K et al. (2018) Live birth outcomes after adolescent and young adult breast cancer. Int J Cancer 142:1994-2002
Gralinski, Lisa E; Sheahan, Timothy P; Morrison, Thomas E et al. (2018) Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. MBio 9:
Au, Kin Man; Tripathy, Ashutosh; Lin, Carolina Pe-I et al. (2018) Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma. ACS Nano 12:1544-1563

Showing the most recent 10 out of 1525 publications